Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of deucravacitinib in Crohn's disease or ulcerative colitis
2020-004461-40Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of deucravacitinib in Crohn's disease and autoimmune colitis (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Safety events. Started May 2021; status: terminated.
02
Drugs
deucravacitinib
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2020-004461-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004461-40.